{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:27Z","timestamp":1791228267135,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment and prevention of human immunodeficiency virus type one (HIV-1) infection was transformed through widespread use of antiretroviral therapy (ART). However, ART has limitations in requiring life-long daily adherence. Such limitations have led to the creation of long-acting (LA) ART. While nucleoside reverse transcriptase inhibitors (NRTI) remain the ART backbone, to the best of our knowledge, none have been converted into LA agents. To these ends, we transformed tenofovir (TFV) into LA surfactant stabilized aqueous prodrug nanocrystals (referred to as NM1TFV and NM2TFV), enhancing intracellular drug uptake and retention. A single intramuscular injection of NM1TFV, NM2TFV, or a nanoformulated tenofovir alafenamide (NTAF) at 75\u2009mg\/kg TFV equivalents to Sprague Dawley rats sustains active TFV-diphosphate (TFV-DP) levels\u2009\u2265\u2009four times the 90% effective dose for two months. NM1TFV, NM2TFV and NTAF elicit TFV-DP levels of 11,276, 1,651, and 397 fmol\/g in rectal tissue, respectively. These results are a significant step towards a LA TFV ProTide.<\/jats:p>","DOI":"10.1038\/s41467-021-25690-5","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T10:03:34Z","timestamp":1631786614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles"],"prefix":"10.1038","volume":"12","author":[{"given":"Denise A.","family":"Cobb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-6761","authenticated-orcid":false,"given":"Suyash","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya N.","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagsen","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagya Laxmi Dyavar","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllyn","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazen","family":"Alnouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5047-0962","authenticated-orcid":false,"given":"Samuel M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-0370","authenticated-orcid":false,"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-9331","authenticated-orcid":false,"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"25690_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci, A. S., Redfield, R. R., Sigounas, G., Weahkee, M. D. & Giroir, B. P. Ending the HIV epidemic: a plan for the United States. JAMA 321, 844\u2013845 (2019).","journal-title":"JAMA"},{"key":"25690_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","volume":"366","author":"B Winner","year":"2012","unstructured":"Winner, B. et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366, 1998\u20132007 (2012).","journal-title":"N. Engl. J. Med."},{"key":"25690_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1192\/bjp.179.4.290","volume":"179","author":"CE Adams","year":"2001","unstructured":"Adams, C. E., Fenton, M. K., Quraishi, S. & David, A. S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 179, 290\u2013299 (2001).","journal-title":"Br. J. Psychiatry"},{"key":"25690_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-041217-013717","volume":"70","author":"RM Gulick","year":"2019","unstructured":"Gulick, R. M. & Flexner, C. Long-acting HIV drugs for treatment and prevention. Annu Rev. Med. 70, 137\u2013150 (2019).","journal-title":"Annu Rev. Med."},{"key":"25690_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen, W. et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J. Acquir Immune Defic. Syndr. 67, 481\u2013486 (2014).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"25690_CR6","unstructured":"CABENUVA. Offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression. https:\/\/www.janssen.com\/janssen-announces-us-fda-approval-cabenuva-rilpivirine-and-cabotegravir-first-long-acting-regimen (2021)."},{"key":"25690_CR7","unstructured":"ViiV Healthcare. Presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing. https:\/\/viivhealthcare.com\/en-gb\/media\/press-releases\/2020\/march\/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-s\/ (2020)."},{"key":"25690_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells, S. et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med 382, 1112\u20131123 (2020).","journal-title":"N. Engl. J. Med"},{"key":"25690_CR9","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz, M. et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 4, e331\u2013e340 (2017).","journal-title":"Lancet HIV"},{"key":"25690_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis, D. A. et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390, 1499\u20131510 (2017).","journal-title":"Lancet"},{"key":"25690_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","volume":"19","author":"TA Kulkarni","year":"2020","unstructured":"Kulkarni, T. A. et al. A year-long extended release nanoformulated cabotegravir prodrug. Nat. Mater. 19, 910\u2013920 (2020).","journal-title":"Nat. Mater."},{"key":"25690_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02885-x","volume":"9","author":"B Sillman","year":"2018","unstructured":"Sillman, B. et al. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. 9, 443 (2018).","journal-title":"Nat. Commun."},{"key":"25690_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jconrel.2019.09.001","volume":"311-312","author":"JR Hilaire","year":"2019","unstructured":"Hilaire, J. R. et al. Creation of a long-acting rilpivirine prodrug nanoformulation. J. Control Release 311-312, 201\u2013211 (2019).","journal-title":"J. Control Release"},{"key":"25690_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1021\/acs.molpharmaceut.9b00871","volume":"17","author":"MG Banoub","year":"2020","unstructured":"Banoub, M. G. et al. Synthesis and characterization of long-acting Darunavir prodrugs. Mol. Pharm. 17, 155\u2013166 (2020).","journal-title":"Mol. Pharm."},{"key":"25690_CR15","doi-asserted-by":"publisher","first-page":"119476","DOI":"10.1016\/j.biomaterials.2019.119476","volume":"223","author":"N Smith","year":"2019","unstructured":"Smith, N. et al. A long acting nanoformulated lamivudine ProTide. Biomaterials 223, 119476 (2019).","journal-title":"Biomaterials"},{"key":"25690_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","volume":"14","author":"B Edagwa","year":"2017","unstructured":"Edagwa, B., McMillan, J., Sillman, B. & Gendelman, H. E. Long-acting slow effective release antiretroviral therapy. Expert Opin. Drug Deliv. 14, 1281\u20131291 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"25690_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0166-3542(92)90026-2","volume":"17","author":"C McGuigan","year":"1992","unstructured":"McGuigan, C., Pathirana, R. N., Mahmood, N., Devine, K. G. & Hay, A. J. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antivir. Res. 17, 311\u2013321 (1992).","journal-title":"Antivir. Res."},{"key":"25690_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem. Pharm. 119, 1\u20137 (2016).","journal-title":"Biochem. Pharm."},{"key":"25690_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1060028016660812","volume":"50","author":"AK Gibson","year":"2016","unstructured":"Gibson, A. K., Shah, B. M., Nambiar, P. H. & Schafer, J. J. Tenofovir Alafenamide. Ann. Pharmacother. 50, 942\u2013952 (2016).","journal-title":"Ann. Pharmacother."},{"key":"25690_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpba.2016.08.022","volume":"131","author":"VM Golla","year":"2016","unstructured":"Golla, V. M., Kurmi, M., Shaik, K. & Singh, S. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate. J. Pharm. Biomed. Anal. 131, 146\u2013155 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"25690_CR21","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/AAC.00656-15","volume":"59","author":"M Gunawardana","year":"2015","unstructured":"Gunawardana, M. et al. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother. 59, 3913\u20133919 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25690_CR22","doi-asserted-by":"publisher","first-page":"119623","DOI":"10.1016\/j.ijpharm.2020.119623","volume":"587","author":"A Sizovs","year":"2020","unstructured":"Sizovs, A. et al. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. Int. J. Pharm. 587, 119623 (2020).","journal-title":"Int. J. Pharm."},{"key":"25690_CR23","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11095-017-2255-7","volume":"34","author":"PK Prathipati","year":"2017","unstructured":"Prathipati, P. K., Mandal, S., Pon, G., Vivekanandan, R. & Destache, C. J. Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model. Pharm. Res. 34, 2749\u20132755 (2017).","journal-title":"Pharm. Res."},{"key":"25690_CR24","doi-asserted-by":"crossref","unstructured":"Hobson, J. J. et al. Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems. RSC Adv. (in the press) (2018).","DOI":"10.1039\/C8RA01944D"},{"key":"25690_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","volume":"294","author":"S Mandal","year":"2019","unstructured":"Mandal, S. et al. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. J. Control Release 294, 216\u2013225 (2019).","journal-title":"J. Control Release"},{"key":"25690_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1994.tb38949.x","volume":"724","author":"DH Katz","year":"1994","unstructured":"Katz, D. H. et al. n-docosanol: broad spectrum anti-viral activity against lipid-enveloped viruses. Ann. N. Y Acad. Sci. 724, 472\u2013488 (1994).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"25690_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0166-3542(02)00105-5","volume":"56","author":"JF Marcelletti","year":"2002","unstructured":"Marcelletti, J. F. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antivir. Res. 56, 153\u2013166 (2002).","journal-title":"Antivir. Res."},{"key":"25690_CR28","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1021\/jm0491400","volume":"48","author":"C McGuigan","year":"2005","unstructured":"McGuigan, C. et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J. Med. Chem. 48, 3504\u20133515 (2005).","journal-title":"J. Med. Chem."},{"key":"25690_CR29","doi-asserted-by":"publisher","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson, P. L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012).","journal-title":"Sci. Transl. Med."},{"key":"25690_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/095632029800900603","volume":"9","author":"C McGuigan","year":"1998","unstructured":"McGuigan, C. et al. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antivir. Chem. Chemother. 9, 473\u2013479 (1998).","journal-title":"Antivir. Chem. Chemother."},{"key":"25690_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/095632029800900202","volume":"9","author":"C McGuigan","year":"1998","unstructured":"McGuigan, C., Tsang, H. W., Sutton, P. W., De Clercq, E. & Balzarini, J. Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency. Antivir. Chem. Chemother. 9, 109\u2013115 (1998).","journal-title":"Antivir. Chem. Chemother."},{"key":"25690_CR32","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1016\/j.bmcl.2016.10.077","volume":"26","author":"S Kandil","year":"2016","unstructured":"Kandil, S. et al. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Bioorg. Med. Chem. Lett. 26, 5618\u20135623 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25690_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3109\/17435390.2010.541292","volume":"5","author":"RF Bressani","year":"2011","unstructured":"Bressani, R. F. et al. Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology 5, 592\u2013605 (2011).","journal-title":"Nanotoxicology"},{"key":"25690_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/nnm.09.71","volume":"4","author":"AS Nowacek","year":"2009","unstructured":"Nowacek, A. S. et al. NanoART synthesis, characterization, uptake, release, and toxicology for human monocyte-macrophage drug delivery. Nanomedicine 4, 903\u2013917 (2009).","journal-title":"Nanomedicine"},{"key":"25690_CR35","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1128\/JVI.01557-14","volume":"88","author":"D Guo","year":"2014","unstructured":"Guo, D. et al. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J. Virol. 88, 9504\u20139513 (2014).","journal-title":"J. Virol."},{"key":"25690_CR36","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. https:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (2020)."},{"key":"25690_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin. Liver Dis. 12, 33\u201334 (2018).","journal-title":"Clin. Liver Dis."},{"key":"25690_CR38","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/S0140-6736(19)30701-9","volume":"393","author":"MS Cohen","year":"2019","unstructured":"Cohen, M. S. Successful treatment of HIV eliminates sexual transmission. Lancet 393, 2366\u20132367 (2019).","journal-title":"Lancet"},{"key":"25690_CR39","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner, V. A. et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30, 1973\u20131983 (2016).","journal-title":"AIDS"},{"key":"25690_CR40","unstructured":"Eggleton, J. S. & Nagalli, S. Highly Active Antiretroviral Therapy (HAART) (StatPearls, 2020)."},{"key":"25690_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","volume":"27","author":"L Chan","year":"2018","unstructured":"Chan, L., Asriel, B., Eaton, E. F. & Wyatt, C. M. Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr. Opin. Nephrol. Hypertens. 27, 102\u2013112 (2018).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"25690_CR42","doi-asserted-by":"publisher","first-page":"112re114","DOI":"10.1126\/scitranslmed.3003174","volume":"3","author":"KB Patterson","year":"2011","unstructured":"Patterson, K. B. et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 3, 112re114 (2011).","journal-title":"Sci. Transl. Med."},{"key":"25690_CR43","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jac\/dkx064","volume":"72","author":"ML Cottrell","year":"2017","unstructured":"Cottrell, M. L. et al. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J. Antimicrob. Chemother. 72, 1731\u20131740 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"25690_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","volume":"286","author":"CYX Chua","year":"2018","unstructured":"Chua, C. Y. X. et al. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J. Control Release 286, 315\u2013325 (2018).","journal-title":"J. Control Release"},{"key":"25690_CR45","doi-asserted-by":"publisher","unstructured":"Johnson, L. M. et al. Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP). Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics11070315 (2019).","DOI":"10.3390\/pharmaceutics11070315"},{"key":"25690_CR46","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","volume":"33","author":"E Schlesinger","year":"2016","unstructured":"Schlesinger, E. et al. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis. Pharm. Res. 33, 1649\u20131656 (2016).","journal-title":"Pharm. Res."},{"key":"25690_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/157016208785861195","volume":"6","author":"A Alexaki","year":"2008","unstructured":"Alexaki, A., Liu, Y. & Wigdahl, B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6, 388\u2013400 (2008).","journal-title":"Curr. HIV Res."},{"key":"25690_CR48","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/jps.24014","volume":"103","author":"N Darville","year":"2014","unstructured":"Darville, N. et al. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. J. Pharm. Sci. 103, 2072\u20132087 (2014).","journal-title":"J. Pharm. Sci."},{"key":"25690_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0192623315618291","volume":"44","author":"N Darville","year":"2016","unstructured":"Darville, N. et al. Modeling the time course of the tissue responses to intramuscular long-acting paliperidone palmitate nano-\/microcrystals and polystyrene microspheres in the rat. Toxicol. Pathol. 44, 189\u2013210 (2016).","journal-title":"Toxicol. Pathol."},{"key":"25690_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2016.03.041","volume":"230","author":"N Darville","year":"2016","unstructured":"Darville, N. et al. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J. Control Release 230, 95\u2013108 (2016).","journal-title":"J. Control Release"},{"key":"25690_CR51","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/AAC.01529-09","volume":"54","author":"G van t Klooster","year":"2010","unstructured":"van \u2019t Klooster, G. et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 54, 2042\u20132050 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25690_CR52","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2017.10.017","volume":"268","author":"BM Jucker","year":"2017","unstructured":"Jucker, B. M. et al. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat. J. Control Release 268, 102\u2013112 (2017).","journal-title":"J. Control Release"},{"key":"25690_CR53","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2352-3018(19)30145-6","volume":"6","author":"MJ Keller","year":"2019","unstructured":"Keller, M. J. et al. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. Lancet HIV 6, e498\u2013e508 (2019).","journal-title":"Lancet HIV"},{"key":"25690_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep45725","volume":"8","author":"M Rodriguez-Garcia","year":"2017","unstructured":"Rodriguez-Garcia, M. et al. Tenofovir inhibits wound healing of epithelial cells and fibroblasts from the upper and lower human female reproductive tract. Sci. Rep. 8, 45725 (2017).","journal-title":"Sci. Rep."},{"key":"25690_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1293\/tox.24.113","volume":"24","author":"K Weber","year":"2011","unstructured":"Weber, K. et al. Pathology in continuous infusion studies in rodents and non-rodents and ITO (Infusion Technology Organisation)-recommended protocol for tissue sampling and terminology for procedure-related lesions. J. Toxicol. Pathol. 24, 113\u2013124 (2011).","journal-title":"J. Toxicol. Pathol."},{"key":"25690_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, 53\u201365 (2018).","journal-title":"Biomaterials"},{"key":"25690_CR57","doi-asserted-by":"publisher","unstructured":"Su, J. T. et al. A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01893-19 (2020).","DOI":"10.1128\/AAC.01893-19"},{"key":"25690_CR58","unstructured":"Denise A. et al. Long-acting tenofovir and nitazoxanide formulations suppress HBV replication. Abstract No. 610. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2020); March 8-11 (Boston, MA, 2020)."},{"key":"25690_CR59","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11095-020-2777-2","volume":"37","author":"SM Simpson","year":"2020","unstructured":"Simpson, S. M. et al. Design of a drug-eluting subcutaneous implant of the antiretroviral tenofovir alafenamide fumarate. Pharm. Res. 37, 83 (2020).","journal-title":"Pharm. Res."},{"key":"25690_CR60","unstructured":"ViiV Healthcare. Announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women. https:\/\/viivhealthcare.com\/en-us\/us-news\/us-articles\/2020\/viiv-healthcare-announces-investigational-injectable-cabotegravir-is-superior-to-oral-standard-of-care-for-hiv-prevention-in-women\/ (2020)."},{"key":"25690_CR61","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2352-3018(19)30342-X","volume":"7","author":"RC Bollinger","year":"2020","unstructured":"Bollinger, R. C. et al. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV 7, e443\u2013e448 (2020).","journal-title":"Lancet HIV"},{"key":"25690_CR62","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1084\/jem.167.4.1428","volume":"167","author":"HE Gendelman","year":"1988","unstructured":"Gendelman, H. E. et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167, 1428\u20131441 (1988).","journal-title":"J. Exp. Med."},{"key":"25690_CR63","doi-asserted-by":"publisher","first-page":"8371","DOI":"10.1039\/C8CC04708A","volume":"54","author":"Z Lin","year":"2018","unstructured":"Lin, Z. et al. ProTide generated long-acting abacavir nanoformulations. Chem. Commun. 54, 8371\u20138374 (2018).","journal-title":"Chem. Commun."},{"key":"25690_CR64","first-page":"3393","volume":"6","author":"S Balkundi","year":"2011","unstructured":"Balkundi, S. et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J. Nanomed. 6, 3393\u20133404 (2011).","journal-title":"Int J. Nanomed."},{"key":"25690_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","volume":"5","author":"AS Nowacek","year":"2010","unstructured":"Nowacek, A. S. et al. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharm. 5, 592\u2013601 (2010).","journal-title":"J. Neuroimmune Pharm."},{"key":"25690_CR66","unstructured":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. National Academies Press (2011)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25690-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T14:42:30Z","timestamp":1669992150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25690-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25690"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25690-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.E. and H.E.G are cofounders of Exavir Therapeutics, Inc. and are inventors on patents that cover stable ProTides and the long-acting slow effective release formulations. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design, data acquisition, analyses, and interpretation, and writing of the paper. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5458"}}